Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model

Xintela's results show that its stem cell product XSTEM®, after injection into a joint with damaged cartilage, migrates to the damage and participates in the regeneration of the cartilage tissue. The results have now been published in the scientific journal Stem Cell Research and Therapy. The study is a research collaboration with the University of Copenhagen with the aim to increase our understanding of XSTEM's mechanisms of action. The results confirm XSTEM's unique properties and great potential in the treatment of osteoarthritis.

"Our results confirm that XSTEM, which consists of integrin α10β1-selected stem cells, has the properties required to repair damaged joint cartilage and is a unique product in the field. By labeling the stem cells, we have been able to show that the injected stem cells migrate to the damaged cartilage, develop into cartilage cells and directly contribute to producing new cartilage tissue. This demonstrates that XSTEM has excellent potential to be a so-called DMOAD (Disease Modifying Osteoarthritis Drug), a treatment that can prevent further degradation of the cartilage in osteoarthritis patients and also be able to regenerate the cartilage and improve joint function. There is currently no DMOAD on the market", says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela has previously shown that the company's integrin α10β1-selected mesenchymal stem cells have a therapeutic effect on cartilage and bone in an osteoarthritis model in horses. In order to increase understanding of XSTEM's mechanisms of action, Xintela has performed additional preclinical studies in collaboration with the University of Copenhagen. Xintela has in a previous press release (May 18, 2021) informed about preliminary results from the study. Clinical studies with XSTEM has recently been initiated in Australia for the treatment of knee osteoarthritis and the company plan to start clinical studies in patients with difficult-to-heal leg ulcers after the summer.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model